ArticleUnited European gastroenterology journal2018

An increased Bax/Bcl-2 ratio in circulating inflammatory cells predicts primary response to infliximab in inflammatory bowel disease patients.

Hamid Asadzadeh Aghdaei et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.